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Purpose: The proportion of the United States population in older adulthood is growing rapidly, and with that growth 
comes an increase in diseases such as cancer. As rates of illness increase, there is a concomitant increase in 
cognitive and psychological correlates of illnesses like cancer. There is evidence that some cancer treatments, 
particularly chemotherapy, affect cognition for cancer patients, although these results are inconsistent. Additionally, 
depression, and other health factors such as activities of daily living (ADLs) have been found to relate to cognitive 
impairment among older adults with cancer. Method: The current study used latent class growth analysis (LCGA) to 
explore longitudinal data from the Health and Retirement Study. The primary goal was to investigate possible 
trajectories of cognitive functioning in older adults diagnosed with, and surviving cancer. Possible psychological, 
health, and demographic predictors of membership in these cognitive trajectories were investigated. Results: 
Findings indicated that three classes of cognitive functioning best fit the data: these were High Recall, Middle Recall 
and Low Recall Classes, which represented fairly stable trajectories from pre-diagnosis to a period four years later. 
Various covariates of class membership were included in the analyses. Treatment with chemotherapy significantly 
predicted membership in the High Recall Class, however this finding is accounted for by an interaction with 
younger age. More symptoms of depression after diagnosis (but not prior to diagnosis) were significantly predictive 
of membership in the Low Recall Class. A higher self-reported probability of living to the age of 85 pre-diagnosis 
predicted membership in the High Recall Class, and greater difficulty with ADLs post-diagnosis predicted 
membership in the Low Recall Class. Finally, individuals in the High Recall Class were significantly more likely to 
be younger, female, and more highly educated, when compared to both the Middle and Low Recall Classes. 
Limitations: The current study is limited by the wide spacing of data collection and dearth of sensitive and varied 
measures of cognitive functioning, which in turn limits the generalizability and specificity of the findings. 
Additionally, a lack of data on cancer type, staging and treatment variables make more nuanced analysis difficult. It 
is not possible to generalize these findings to individuals who passed away within two years of their diagnosis, not 
to individuals of minority status, who were underrepresented in this sample. Conclusions: These results may inform 
the understanding of cognitive functioning in older adults surviving cancer, as it relates to psychological, 
demographic and other health factors, with implications for timing and targeting of interventions.
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Chemotherapy for Cancer and the Aging Brain: Blessing or Burden?  
	   	  
	   In the current era, the United States population is living longer, with the number of 
individuals over the age of 65 expected to double in the next 25 years (Kinsella & Wan, 2009). 
However, as the population ages, there is a marked increase in the prevalence of many age-
related diseases (Hebert, Scherr, Bienias, Bennett, & Evans, 2003; Yancik, 1997), including 
cancer. In fact, research has shown that the single most common risk factor for cancer is aging, 
with over 60% of cancers diagnosed in individuals over the age of 65 (Howlader et al., 2011; 
Smith, Smith, Hurria, Hortobagyi, & Buchholz, 2009).  
 Though epidemiologic studies have shown a stabilization of cancer incidence rates, as 
well as a decrease in deaths overall, older adults in general and older women and minorities in 
particular are still at the greatest risk of mortality (Edwards et al., 2002). As risk factors for 
cancer death have been investigated, so too have associations with survivorship, particularly as 
the number of cancer survivors increases, and continues to age. Indeed, it is estimated that by the 
year 2020, 63% of cancer survivors will be over the age of 65 (Hewitt, Rowland, & Yancik, 
2003). Just as cancer is associated with general health, psychological, and cognitive problems 
among older adults, so too does survivorship impact health comorbidities, psychological distress, 
and difficulties with instrumental activities of daily living (Gotay & Muraoka, 1998). 
The increase in cancer incidence, as well as the greater chance of survival due to early 
detection and advances in treatment, means that more individuals may encounter the neurotoxic 
side effects of certain treatments – particularly physical effects such as the nausea, vomiting and 
hair loss associated with chemotherapy (Argyriou, Assimakopoulos, Iconomou, 
Giannakopoulou, & Kalofonos, 2011). Cognitive changes during a course of treatment with 
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chemotherapy have been reported as well, including difficulty with memory, attention, and 
concentration (Ahles et al., 2002; Vardy & Tannock, 2007). Though reports of “chemo fog” or 
“chemo brain” have appeared in the literature since the 1970’s (Silberfarb, 1983), inconsistencies 
in research findings and methodological problems have impeded generalization. Of particular 
relevance is the dearth of studies investigating post-chemotherapy cognitive impairments in older 
adults. 
 There have been inconsistent findings in studies of chemotherapy for cancer and 
cognition in late life. These inconsistencies have been attributed to depressive symptoms 
associated with chemotherapy, other health comorbidities, and degree of cognitive impairment 
prior to treatment (Ahles & Saykin, 2007). Additionally, there are many studies that have failed 
to observe any cognitive changes after treatment with chemotherapy across a range of cancer 
types and patient demographics; including gender, age and education level (e.g. Donovan et al., 
2005; Jenkins et al., 2006; Keating, Nørredam, Landrum, Huskamp, & Meara, 2005; Porter, 
2013; Shaffer et al., 2012), with other studies reporting a range of cognitive difficulties from the 
start of treatment to long after the onset of remission (Ahles et al., 2002; Argyriou et al., 2011; 
Vardy & Tannock, 2007). Along with the inconsistency in results, heterogeneity in regard to 
demographic and other health factors further complicate the present understanding of the 
relationship between cognition and cancer in late life. 
 Regardless of the many challenges, there has been an increased focus on chemotherapy-
induced cognitive impairment (CICI) in the literature, with particular interest in finding which 
individuals are most likely to be at risk, what treatment circumstances evoke the greatest amount 
of risk, and how survivors of cancer may be affected over time (e.g.; Ahles et al., 2002; 
Anderson-Hanley, Sherman, Riggs, Agocha, & Compas, 2003; Tchen, et al., 2003; Vardy & 
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Tannock, 2007; Vearncombe & Pachana, 2009). Although the number of studies on CICI has 
increased, Wefel and Schagen (2012) found that of 53 studies published between 1995 and 2012, 
individuals over the age of 50 were studied in only six (11% of studies). Although half of the 
women diagnosed with breast cancer are over the age of 65, only two studies have been 
published about this age group. This discrepancy between research populations and patient 
populations is complicated by the ageism already documented in hospital settings treating older 
adult patients (Bond et al., 2003; Janssen-Heijnen et al., 2007; Peake, Thompson, Lowe & 
Pearson, 2003). Furthermore, the paucity of research about older adults raises the possibility that 
older patients may not only be at greater risk for cognitive side effects of cancer treatment 
(Heflin et al., 2005; Heflin, Pollak, Kuchibhatla, Branch, & Oddone, 2006), but that their treating 
physicians may also assume that any cognitive deficits are attributable to age, rather than to the 
side effects of treatment (Schroyen, Adam, Jerusalem, & Missotten, 2015).  
 Finally, as the population ages, the cognitive and emotional functioning of older adults 
has wide-ranging implications for the quality of life and meaning in later life, as well as for 
families, communities and society at large. In light of emerging research indicating the 
importance of contributions to society by older adults, many of whom are prosocial (Midlarsky 
& Hannah, 1989; Midlarsky & Kahana, 2007; Kahana, Bhatta, Lovegreen, Kahana, & 
Midlarsky, 2013; Midlarsky, Kahana, & Belser, 2015), it is especially vital to study the effect of 
cancer treatment and other health outcomes associated with cancer on cognitive competence, and 
on functioning in daily life. Additionally, with the increased rates of survival from cancer, it is 
vital to investigate the cognitive, physical, and emotional functioning both among older adults 
with active cancer and those in remission. Thus, this study was designed as a longitudinal 




Cognitive impairment associated with chemotherapy 
 Chemotherapy-induced cognitive impairment (CICI) has been found to include 
impairment of memory, learning, concentration, attention, executive function, processing speed 
and visuospatial skills in numerous articles (e.g. Anderson-Hanley et al., 2003; Argyriou et al., 
2011; Kreukels, Schagen, Ridderinkhof, Boogerd, Hamburger & van Dam, 2005; Wefel & 
Schagen, 2012). Estimates of the duration of these symptoms range from the period concurrent 
with treatment to a persistence during the period when the patient is in remission (Argyriou et al., 
2011; Kreukels et al., 2006; Vardy & Tannock, 2007). Indeed, several clinical studies estimated 
that the prevalence of long-term cognitive impairment after chemotherapy (CICI) affects 
between 16% and 75% of patients. This is even after controlling for the severity of cancer, 
psychological symptoms and demographic factors (Anderson-Hanley et al., 2003; Kreukels et 
al., 2006; Tchen, et al., 2003; Vardy & Tannock, 2007).  
 The neuropsychological dysfunction reported in association with chemotherapy has been 
somewhat inconsistent across studies (Vardy & Tannock, 2007), although it is usually described 
as primarily related to attention, verbal and visual memory, and processing speed. These deficits 
are often understood in the context of the Reitan/Wolfson assessment model of 
neuropsychological functioning (Reitan & Wolfson, 2003), which describes the way information 
is processed from external stimuli, and ultimately encoded for later retrieval. The model posits 
that a certain degree of alertness and ability to sustain attention and concentration is required in 
order for sensory areas to process information, which is then encoded in deeper, subcortical 
structures. It is possible, then, that if initial attention is compromised due to neurotoxic side 
effects of treatment, that encoding and subsequent retrieval attempts will be compromised as 
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well (Anderson et al., 2000). Indeed, similar cognitive difficulties have been described in 
illnesses such as Parkinson’s disease and HIV, with or without adjuvant treatment that might 
compromise neuropsychological abilities (Butters et al., 1990; Massman, Delis, Butters, Levin, 
& Salmon, 1990; Whittington, Pod, & Kan, 2000). 
 Many variables have been investigated as possible risk factors for the development of 
these cognitive impairments, including structural brain changes, type of cancer, type and dosage 
of chemotherapy agent, degree of cognitive impairment prior to the cancer diagnosis, and other 
health, psychological and demographic correlates (e.g. Ahles & Saykin, 2007; Vardy et al., 2006; 
Wefel & Schagen, 2012). The multitude of associated factors, and the limited knowledge of their 
complex interplay, certainly complicates the ability to isolate specific predictors and effects of 
chemotherapy on cognition. 
Of particular relevance, cognitive impairment prior to treatment (and even prior to cancer 
diagnosis) would place an individual at greater risk for developing CICI (Ahles & Saykin, 2007; 
Cimprich et al., 2010). There may be genetic factors that predispose an individual to developing 
both cancer and cognitive impairment in late life, though it is nearly impossible to disentangle 
the multitude of possible factors involved, particularly among older adults (Rolig & McKinnon, 
2000). Additionally, lifestyle choices throughout adulthood are likely to affect both cognitive 
impairment and risk factors for cancer. For example, smoking has been shown to place 
individuals at risk for dementia, and is a known cause of lung cancer – a link that is especially 
salient for the current cohort of older adults (Anstey, von Sanden, Salim, & O'Kearney, 2007). 
The cancer patients most frequently studied in regard to cognitive impairment after 
chemotherapy are breast cancer survivors (e.g. Brezden, Phillips, Abdolell, Bunston, & Tannock, 
2000; Castellon et al., 2004; Falleti, Sanfilippo, Maruff, Weih, & Phillips, 2005; Zunini et al., 
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2013). It is difficult to determine whether breast cancer survivors are more studied because they 
have the greatest incidence of CICI, or for other reasons. For example, they may be more 
frequently studied because the fact the higher survival rate makes any treatment side effects, 
including cognitive impairment after chemotherapy, both more salient and more likely. Another 
possibility is that they are frequently studied because of the social and political organizing 
around survivors’ issues evokes interest and attention (Corbett & Mori, 1999; King, 2004).  
It is also the case that the effect of chemotherapy on cognitive functioning has received 
more attention for individuals with non-central nervous system (CNS) cancers such as breast 
cancer, than CNS cancers. This is likely due to the fact that cognitive impairment associated with 
CNS cancer is more likely to be a result of the cancer itself rather than the treatment, since CNS 
cancer often affects the brain (Ahles & Saykin, 2007). Indeed, there have been reports of 
chemotherapy improving cognition in CNS cancers, in cases in which chemotherapy has the 
result of reducing the size and effect of these cancers (Hilverda et al., 2010; Wefel et al., 2011; 
Wefel & Schagen, 2012). Although some cancers have received more attention than others in 
their association with CICI, several studies have failed to find a significant relationship between 
cancer type and stage on outcomes associated with chemotherapy (e.g. Burton, Galatzer-Levy, & 
Bonanno, 2014; Hipkins, Whitworth, Tarrier, & Jayson, 2004). 
In regard to brain changes associated with adjuvant treatment, magnetic resonance 
imaging (MRI) studies of cancer patients who have undergone chemotherapy have found a 
reduction of volume in the frontal cortex, along with demyelination of white matter tracts, both 
of which have been associated with deficits in working memory and executive functions (Saykin, 
Ahles, & McDonald, 2003; Stemmer, Stears, Burton, Jones, & Simon, 1994). When functional 
magnetic resonance imaging (fMRI) has been used to assess brain activity during a working 
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memory task, a decrease in overall brain activation has been reported among breast cancer 
survivors who underwent adjuvant chemotherapeutic treatment, compared to healthy controls 
(Zunini et al., 2013). It is worth noting, however, that some of the patterns of lessened activation 
of the bilateral insula, orbitofrontal cortex, and left insula were explained not only by recent 
treatment with chemotherapy, but also by pre-treatment differences, including depression, 
anxiety and fatigue (Cimprich et al., 2010; Zunini et al., 2013). These findings suggest that there 
may be an interaction between neurotoxic factors and diverse physical and psychological 
processes for many patients. 
Though several studies have found links between chemotherapy and cognitive 
impairment (for reviews, see Ferguson & Ahles, 2003; Vardy & Tannock, 2007), many of the 
findings have been inconsistent, and methodological limitations have raised concerns about the 
generalizability of the findings. These limitations include sampling individuals after they have 
been diagnosed, small sample sizes, and lack of prospective data on various health and cognitive 
indices among participants. As previously noted, a wide range of prevalence estimates have been 
reported, with different rates reported across studies, and some failing to find any effect of 
chemotherapy at all (e.g. Donovan et al., 2005; Jenkins et al., 2006; Keating, Nørredam, 
Landrum, Huskamp, & Meara, 2005; Porter, 2013; Shaffer et al., 2012). Additionally, studies 
subsequent to those initially showing cognitive deficits have reported no discernible differences 
several years following treatment (Schagen et al., 2002). These studies raise questions about the 
ability to reliably discern CICI among cancer patients after treatment and into remission, as well 
as whether the cognitive impairments observed are actually a result of treatment with 
chemotherapy. Further, the interplay of demographic factors with comorbid health and 




Depression and cognition in cancer  
In many studies of CICI, factors such as fatigue, and psychological distress, particularly 
depression and anxiety, have been cited as possible confounds of the relationship between 
chemotherapy and cognitive impairment (Phillips & Bernhard, 2003; Tchen et al., 2003). Indeed, 
these variables have been found to relate to cognitive functioning even in the absence of a cancer 
diagnosis (Massman, Delis, Butters, Dupont, & Gillin, 1992). These deficits have anatomical 
correlates, such as subcortical dysfunction, and neuropsychological correlates that are very 
similar to those associated with chemotherapy and cancer, Parkinson’s disease, and HIV, among 
others (Butters et al., 1990; Massman, Delis, Butters, Levin, & Salmon, 1990).  
Symptoms of psychopathology have long been associated with diagnosis and treatment of 
cancer of various types, and have been shown to persist long after remission among certain 
individuals (e.g. Burgess et al., 2005; Chochinov, 2001; Derogatis et al., 1983). Furthermore, 
depression and anxiety symptoms are often associated with cognitive deficits that may mimic 
neurotoxic symptoms associated with chemotherapy (McClintock, Husain, Greer, & Cullum, 
2010; Silberfarb, Philibert, & Levine, 1980).  Depression alone has been implicated as a risk 
factor for cancer and other stress-related health problems, with higher rates post-diagnosis than 
for other major medical conditions (Polsky et al., 2005). The added burden of depression may 
also incur greater allostatic load (accumulation of negative health factors; McEwen, 1998). The 
comorbidity of cancer and depression is associated with poorer outcomes than either cancer or 
depression alone (Moussavi et al., 2007). Additionally, treatment with chemotherapy has been 
shown to be associated at onset and/or increase depression among adults and older adults with 
cancer, even years after diagnosis (Burton, Galatzer-Levy, & Bonanno, 2014). 
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What makes the separation of the depression from the biological impact of chemotherapy 
so difficult is that even if cognitive impairment is neurobiological or genetic in origin, 
individuals may have symptoms of depression resulting from their decrement in functioning and 
lower quality of life after treatment (Castellon et al., 2004; Harrington, Hansen, Moskowitz, 
Todd, Feuerstein, 2010; Jenkins et al., 2006). These issues demonstrate how important it is to 
investigate these topics prospectively, in an attempt to establish whether psychological or 
biological variables (or a combination), are risk factors or consequences of cognitive deficits in 
cancer patients (Jenkins et al, 2006). Furthermore, it is possible that contributing factors have 
differential effects at different ages. Indeed, much of the research that has been done fails to take 
into consideration the specific challenges faced by older adults with cancer. 
Cognition in late life 
 While cognition in older adults may be further compromised by medical issues such as 
cancer, there is a certain amount of decline in domains such as attention and rote verbal memory 
that is associated with normal aging  (Craik, 1994). Indeed, studies of healthy, cognitively intact 
older adults have shown profiles of working memory that resemble young adults with divided 
attention and executive dysfunction, indicating that some decline in the ability to attend to, 
process, and ultimately encode information is expected with age (Anderson et al., 2000). 
 Demographic characteristics have been associated with cognition in late life as well, with 
the level of education and intelligence often cited as protective factors, leading to the concept of 
cognitive reserve. Cognitive reserve leads to slowing down of functional decline even in the 
presence of neurodegeneration (Stern, 2003). On the other hand, other studies have shown lower 
levels of education to be protective against cognitive decline in late life, possibly because of a 
floor effect for such individuals on neuropsychological testing (Ardila, Ostrovsky-Solis, Rosselli, 
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& Gomez, 2000). Factors, such as gender, race, and age are related to cognitive impairment, with 
the oldest women generally exhibiting the steepest decline (Proust-Lima et al., 2008), though this 
may be accounted for by gender discrepancies in life expectancy and historical barriers to higher 
education for women and minorities. Additionally, lower socioeconomic status across the 
lifespan is associated with cognitive decline (Rabbitt, Donlan, Watson, McInnes, & Bent, 1995). 
 In addition to normal change in cognition associated with aging, and demographic 
correlates of cognitive impairment, the presence of comorbid health concerns (physical and 
psychological) have been shown to affect neuropsychological outcomes (Comijs, Deeg, Dik, 
Twisk, & Jonker, 2002; Seeman, McEwen, Rowe, & Singer, 2001). Some studies have even 
shown relationships among self-perceptions of health status and cognition (Shrira et al., 2011), 
and on depression, that is also related to cognition in late life (Cole & Dendukuri, 2003). This 
may be especially problematic for those who believe that physical, emotional and cognitive 
decline are inevitable parts of the aging process, as these individuals may be less likely to seek 
preventive health care services (Sarkisian, Hays, & Mangioni, 2002). 
 Finally, cognition has been associated with functional indices, particularly the ability to 
perform activities of daily living (ADLs) such as walking one block, standing up from a sitting 
position without assistance, and taking care of one’s own personal hygiene (Freedman et al., 
2013). Indeed, cognitive changes among older adults have been associated with lower fluency 
with ADLs in a number of studies (McGuire, Ford, & Ajani, 2006). In addition, difficulty with 
physical tasks, exercise, and a more stationary lifestyle have been associated with impaired 
cognition (Tabbarah, Crimmins, & Seeman, 2002), though at times this association has been 
bolstered by other factors like depression (Atkinson et al., 2007). As most older adults, even 
those considered healthy, experience some comorbid medical conditions and declines in 
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functioning (Freedman et al., 2013), adding the additional burden of an illness as serious as 
cancer can increase the likelihood of impairment.  
Factors associated with cancer in late life 
 Cancer and cancer treatment in late life are increasingly important as the United States 
population ages (Krtolica & Campisi, 2002). Additionally, it is estimated that by the year 2030, 
70% of new cancer diagnoses will be made in individuals over the age of 65 (Smith et al., 2009). 
With these facts in mind, it is vital that an emphasis be placed not only on the effective treatment 
of cancer in the elderly, but also on the quality of life and psychosocial issues associated with 
illness and treatment in this population. Integrative research is particularly important because of 
the heterogeneity of older adults in every domain, from cultural concerns, to physical and 
cognitive functioning, to educational level, to economic status (Puts, Papoutsis, Springall, & 
Tourangeau, 2012). 
Among older adults, as in younger people, cancer diagnosis, treatment and survivorship 
have been associated with psychological distress (e.g. Burgess et al., 2005; Chochinov, 2001). 
Indeed, one study found that over 25% of late life long-term cancer survivors evidenced clinical 
levels of depression (Deimling, Kahana, Bowman, & Schaefer, 2002). Because depression and 
other psychological issues are also associated with cognitive deficits, medical illness, and quality 
of life concerns (Butters et al., 2000; Blazer, 2003), understanding the interplay of depression 
with cancer and other functional concerns in this population is extremely important. 
Additionally, it is increasingly clear that responses to cancer diagnosis and treatment are 
influenced by the aging process (Hurria, Naylor, & Cohen, 2013). For example, because age- 
related physiological changes occur in the renal and hepatic systems of older adults, there are 
barriers to efficacious pharmacotherapy interventions in the sense that chemotherapies may be 
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harmful to the aging liver and kidney (Puts et al., 2012). It is also vital to address the fact that 
older adults with new diagnoses of cancer are likely to have other comorbid health concerns that 
could affect their prognosis, treatment options, and chance of survival (Yancik, Ganz, 
Varricchio, Conley, 2001). Additional barriers, such as poverty, stigma related to cancer, and 
lack of access to pertinent information regarding diagnosis and treatment will contribute to the 
difficulty of getting good medical care among older adults, particularly among minority group 
members (Hurria et al., 2008). Because of these and other related issues, it is possible that cancer 
deaths will increase in the coming decades (Smith et al., 2009).  
Finally, ageism in the medical treatment of older adults, especially in hospital settings, 
has been widely documented. Some studies have found negative attitudes toward elderly patients 
most prevalent in doctors uninterested in working with older people, often because it’s “not 
worth it” since the older individual has “lived long enough” that they may fail to thrive even if 
cured, or hasn’t many years to live anyway (Leung, LoGiudice, Schwarz, & Brand, 2011). 
Certain physicians rate older people as having low eligibility for cancer screening, treatment and 
participation in clinical research trials based on both on chronological age and on medical 
comorbidities (Heflin, Pollak, Kuchibhatla, Branch, & Oddone, 2006; Schroyen, Adam, 
Jerusalem, & Missotten, 2015). This ageism is particularly distressing in light of research 
showing that older adults primed with negative stereotypes about aging evidenced a weaker will 
to live than those not exposed to ageist stereotypes (Levy, Ashman, & Dror, 2000). Additionally, 
an individual’s subjectively perceived health status has been found to independently predict 
mortality (Idler & Benyamini, 1997), highlighting the importance of positive interactions with 
medical professionals around identity issues related to age and illness. Fortunately, there has 
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recently been an increase in effort to train oncologists and other clinicians to be competent at 
working with older adults (Hurria et al., 2008).  
Limitations of existing research 
 There are many limitations to the existing research on cognitive changes in cancer, 
including those associated with chemotherapy. These limitations make it difficult to generalize 
findings, gain consensus among scientists about implications for various patient populations, 
predict outcomes over time and, importantly, to develop effective cognitive interventions for 
suffering patients. The most serious limitations are sampling biases, the fact that most research is 
cross-sectional rather than longitudinal, and the dearth of research addressing these phenomena 
in older adults. 
Even though CICI has been reported and studied for several decades, there is a surprising 
lack of measurement instruments for assessing cancer-related cognitive functioning (Vardy et al., 
2006). There are other difficulties as well, such as sampling and methodological biases 
associated with studies of patient populations - for example, arbitrary cutoff points for measures, 
small sample sizes, pre-existing differences among patients sampled, and the relative paucity of 
follow-up data collection (Altman & Lyman, 1998). Furthermore, the measures used may not be 
sensitive enough to measure changes over time, particularly if those changes are small. An 
additional problem is that many of the measures used have practice effects, and patients may be 
re-tested too soon for these effects to wear off (McCaffrey, Duff, & Westervelt, 2000; Salinsky, 
Storzbach, Dodrill, & Binder, 2001). The use of neuropsychological tests designed to measure 
baseline cognitive functioning may not capture subtle changes in executive functioning and 
working memory, especially for older adult patients (Au et al., 2004; Salthouse, 2009).  
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 Perhaps the most serious limitation to the existing research on CICI is that most studies 
have been cross-sectional rather than longitudinal (Argyriou et al., 2011). The lack of testing at a 
time prior to diagnosis and treatment onset as well as long-term follow up in these samples 
renders it difficult to establish a temporal relationship between cognitive capacity and treatment 
(Campbell, Stanley, & Gage, 1963). Some prospective studies have been undertaken in the past 
few years. However, even these studies do not clearly separate cancer diagnosis from the other 
factors that may affect cognitive functioning (e.g. Falleti et al., 2005; Minsini et al., 2008; Zunini 
et al., 2013). Further study is needed in large, nationally representative samples followed over a 
period of years, with data collected in a context unrelated to cancer diagnosis or treatment to 
limit expectancy effects and other response biases (Juster & Suzman, 1995; Rosenthal, 1965). 
In addition to the problematic nature of some research designs employed to test 
hypotheses about CICI, there is also the sampling difficulty inherent in the heterogeneity of types 
of cancer and the diverse treatments administered. This is true particularly when small sample 
sizes are used (Vardy, et al., 2006), people are sampled only after their diagnoses (Vardy et al., 
2006), and when other factors such as mood are not controlled (Phillips & Bernhard, 2003). 
Certainly, there is considerable heterogeneity in the demographic and health characteristics of 
cancer patients and survivors, particularly in late life (Jung & Wickrama, 2008).  
 Several recent studies on cognitive functioning in late life have found no evidence that 
chemotherapy affects cognitive functioning (Keating et al., 2005; Porter, 2013). However, these 
studies did not assess more nuanced changes in cognition over time, and failed to identify 
significant covariates. One study that employed a longitudinal design demonstrated that 
chemotherapy had a significant impact on persistent depression among cancer survivors, when 
these survivors were compared with those who received other forms of treatment (Burton, 
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Galatzer-Levy, & Bonanno, 2014). This indicates the importance of continuing to investigate the 
impact of chemotherapy and other health and mood factors on cognition in late life. Such studies 
should employ sensitive research designs, such as prospective longitudinal designs, and 
statistical techniques such as latent growth modeling (Jung & Wickrama, 2008). 
The current study 
 Current research focusing on post-cancer cognitive impairment suggests that 
demographic factors, treatment with chemotherapy, poor health and functioning, and depressive 
symptoms are all significantly related to cognitive functioning after treatment. However, many of 
these studies are cross-sectional in design, and among those with a prospective design, few have 
measured cognitive functioning prior to diagnosis. Additionally, many studies lack a comparison 
group, particularly those diagnosed with cancer that received other types of treatment 
(particularly radiotherapy or surgical intervention), and did not receive chemotherapy. This study 
offers a unique opportunity to analyze prospective data within an understudied population over 
time, with implications for intervention and treatment. 
The current study will employ longitudinal data in order to analyze cognitive functioning 
from the period two years prior to cancer diagnosis, to the time point immediately following 
diagnosis and initial treatment (at which point the greatest treatment effects may be observed), 
and then to the period four years after the start of treatment. Additionally, hypothesized 
demographic, health and psychological predictors of cognitive functioning will be investigated 
among older adults diagnosed with cancer.  
 It has been increasingly clear in the last several decades of research that older adults 
continue to contribute to society long after retirement. Emerging research on prosocial behavior 
in late life indicates that individuals are eager to help others, even if they are not in perfect health 
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themselves (Midlarsky & Hannah, 1989; Midlarsky & Kahana, 2007; Kahana et al., 2013; 
Midlarsky, Kahana, & Belser, 2015). Because of the rapid aging of the United States population 
and the associated implications for society (in terms of cost of care), it is valuable to seek greater 
understanding of factors that might impede older individuals from aging successfully, and from 
experiencing life as meaningful after cancer treatment. 
Hypotheses and research questions 
In previous research, factors such as demographic factors, treatment with chemotherapy, 
functional and health concerns, and depressive symptoms have been found to be associated with 
impairment in cognitive functioning after treatment. In this study of older adults, it is 
hypothesized that the relationships among these variables will be similar to those found in the 
literature. It is predicted that exposure to treatment with chemotherapy (Vardy & Tannock, 
2007), and depressive symptoms (Burton, Galatzer-Levy, & Bonanno, 2014), will predict 
cognitive decline over time, in addition to other demographic and functional factors. The 
hypotheses, followed by the research question, are as follows. 
1. In older adult cancer patients, treatment with chemotherapy will be associated with lower 
cognitive functioning over time, compared with treatment with radiation or surgery. 
2. More depressive symptoms following diagnosis and onset of treatment will predict lower 
cognitive functioning over time. 
3. Difficulty with ADLs following diagnosis and onset of treatment will predict lower 
cognitive functioning over time. 




5. Will a higher subjective health rating prior to diagnosis predict better cognitive 
functioning over time, even after diagnosis and treatment? 
Method 
Participants 
The sample consists of participants in the Health and Retirement Study (HRS), an 
ongoing study sponsored by the National Institute on Aging (grant number NIA U01AG009740), 
collected by scientists at the University of Michigan. This study was undertaken to better 
understand various aspects of aging among Americans, including health factors. It began in 
1992, with sample of individuals born between 1931 and 1941. Every six years, a new cohort of 
older adults has been added to the sample (such as the War Baby, Children of Depression Era, 
and Early Baby Boomer cohorts), while previous samples continued to be interviewed along with 
their spouses. Three of the five groups sampled thus far came from an initial sampling effort in 
1992, when 69,337 households were screened for eligible participants. Of this number, 59,918 
households were identified as eligible (Juster & Suzman, 1995), and a multi-stage, clustered area 
probability frame approach was used to select 15,497 participants (Sonnega et al., 2014). 
Subsequent cohorts were sampled from the Medicare enrollment database. Ultimately, face-to-
face interviews of selected participants and their spouses (oversampling for certain minority 
groups; Juster & Suzman, 1995) have been conducted every two years since 1992. Results of the 
most recent wave of data were released in the year 2012. For each wave, response rates were 
between 88% and 89.4%. These data have been archived, and are available to the public as well 
as to researchers. For the purposes of this study, a consolidated data file compiled by the RAND 





In this study, data collected every two years (beginning in 1992), from American older 
adults, will be utilized. The HRS dataset includes the measurements of cognitive functioning 
collected two years before cancer diagnosis, and then three times after diagnosis, with two years 
between each of the collection points. Also measured are treatment type received, demographic 
factors, depressive symptoms, health and activities of daily living (ADLs).  
The selection criteria for participants for this study were answers of “yes,” they had not 
previously reported a cancer diagnosis and “yes,” they had developed cancer since the most 
recent interview. Participants were not excluded from the analysis if they did not report 
information on the type of cancer treatment received. Data were collected using a floating 
baseline methodology (e.g. Burton, Galatzer-Levy, & Bonanno, 2014). A floating baseline 
methodology entails anchoring participants’ data to the year of cancer diagnosis, so that 
comparisons can be made among individuals who were diagnosed in different years. Only 
individuals who were still alive four years after their initial cancer diagnosis, and had completed 
cognitive testing as part of the HRS data collection in at least three interviews, were included in 
the analyses, both to identify long-term outcomes among cancer survivors, and for purposes of 
optimal model convergence. 
 Based on the above selection criteria, 403 participants were included in the analyses (see 
Table 1 for demographic characteristics). Participants consisted of 52.3% males and 47.1% 
females, with 86.6% identifying as Caucasian, 12.4% as African American, and 1.0% as of 
another race/ethnicity. Mean age of the sample at diagnosis was 76.15 years (SD = 8.0), with an 
average of 11.51 years of education completed (SD = 3.64). At the time of diagnosis, 57.1% of 
participants were married, 5.2% were divorced, 30.3% were widowed, and 7.4% endorsed a 
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different relationship status such as partnered or separated. Data about non-housing financial 
assets post-diagnosis were collected at each wave, and are reported in Table 1. Of the sample, 
37.7% reported having less than $10,000 in assets, 30.8% reported having between 10,000 and 
100,000, and 28.3% reported having more than 100,000 in non-housing financial assets at the 
time point immediately following diagnosis. 
Measures 
Cancer status. At each wave of data collection, participants were asked whether they had 
a diagnosis of cancer that they had not had in the previous wave of data collection. Data 
collected for cancer status was based on an individual answering “yes” to the question of 
whether they had developed cancer since their most recent interview, and had no prior history of 
cancer. 
Treatment type. If a participant responded “yes” to the question about having been 
diagnosed with cancer since the previous wave of data collection, they were asked subsequent 
questions about treatment regimen, including whether they received chemotherapy, radiation, 
surgery or other. These variables were dummy coded for purposes of analysis, so that those who 
had treatment data available were either coded as “1” for answering “yes” to receiving a 
particular treatment, or “0” for “no.” The three treatment types coded were chemotherapy, 
radiation and surgery. Of the 450 participants, treatment data were available for 235, with 46.8% 
of the treatment subsample reporting exclusively receiving chemotherapy, 32.3% receiving 
surgery, and 20.8% reporting that they received radiation. 
Individual characteristic variables. Gender was measured in this study as a dichotomous 
variable, either female (“1”) or male (“0”). Race data were also used, specifically whether the 
participants were White/non-Hispanic (“1”), Black (“2”), or Hispanic (“3”) - the three major 
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racial groups sampled in the HRS. Age at cancer onset was calculated, as well the highest level 
of education completed in number of years (among other demographic variables reported in 
Table 1). 
Cognitive functioning. For cognitive functioning, a measure was chosen to capture the 
common complaints associated with chemotherapy – specifically attention, working memory and 
long-term verbal memory. The Health and Retirement Study (HRS) reports a composite variable 
of both immediate and delayed recalled trials of a memory task, in which participants were asked 
to remember a list of unrelated nouns presented to them verbally (10 words to be recalled 
immediately after stimulus presentation, and then again 30 minutes later). This variable is called 
“total recall,” and ranges from 0-20 (10 possible points for words recalled in the immediate trial, 
and 10 possible points for words recalled in the delay). This task measures attention and working 
memory, in addition to memory storage and retrieval. In this sample, prior to diagnosis, there 
was a mean total recall score of 8.97 (SD = 3.64). After diagnosis, the sample had a mean total 
recall score of 8.58 (SD = 3.42).  
Though some have argued that a full neuropsychological testing battery is needed to 
assess cognitive performance (Vardy, Rourke, & Tannock, 2007), it is not possible for studies 
like the HRS due to time constraints and resources. Additionally, research has shown that a 
limited battery with fewer, more targeted assessments, such as the verbal memory test used in 
this study, are just as effective at assessing changes in cognitive functioning over time (Freeman 
& Broshek, 2002; Taylor & Heaton, 2001).  
Depression. The HRS utilized an abbreviated 8-item version of the Center for 
Epidemiologic Studies – Depression scale (CES-D), asking participants whether they 
experienced any of 8 symptoms (yes or no) during the previous week (such as “I could not get 
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going” and “I felt depressed”). This scale has shown high internal consistency and construct 
validity (Radloff, 1977), and Cronbach’s alphas of .80 and above (Kohout, Berkman, Evans, & 
Cornoni-Huntley, 1993). In the current study, CES-D scores had an alpha of .81. Prior to 
diagnosis, the mean depression score in the sample was 1.34 (SD = 1.80). After diagnosis, the 
mean depression score was 1.83 (SD = 2.03). As the clinical cutoff for this short form of the 
CES-D is a score of 4 (Steffick, 2000), the sample was well below the clinical level for 
depression overall at both time periods. 
Self-reported health. Subjective health status data were collected at each time point by 
asking participants to rate their overall health on a 5-point scale ranging from 1=excellent to 
5=poor.  These subjective health ratings have been found to be reliably consistent predictors of 
mortality (Idler & Benyamini, 1997). Before diagnosis, the mean health score was 2.91 (SD = 
1.11), with a mean score of 3.52 (SD = 1.05) after diagnosis. 
Activities of daily living (ADLs). Activities of daily living (ADLs) were defined in the 
HRS in several ways, for example being able to walk one block, to stand up after sitting without 
help, dress oneself, and care for personal hygiene. After these ADLs were assessed individually, 
a composite measure of difficulty with ADLs was collected, asking participants to rate their 
difficulty with these activities on a scale from 0=no difficulty to 5=extreme difficulty. When 
assessed at the time point prior to diagnosis, a mean of 0.35 (SD = 0.85) was reported, with a 
mean of 0.47 (SD = 0.99) at the time shortly after diagnosis. 
Optimism about future outcomes. Participants were asked about the probability of future 
outcomes regarding personal, economic and health events. These included such questions as 
whether they expected to “live to be 75 or more,” “live to be 85 or more,” “see another economic 
depression,” “leave an inheritance,” and others. The questions were asked on a scale of 
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0=absolutely no chance to 10=absolutely certain, and subsequently multiplied by 10 so as to 
have a probability distribution ranging from 0 to 100%. In many studies, this measure has been 
used as a proxy for optimism about the future (e.g. Galatzer-Levy & Bonanno, 2014). Alhough 
data based on this measure were only collected in early waves of the HRS, there were subsequent 
data for the preliminary analyses. Prior to diagnosis, the self-rated probability of living to the age 
of 75 was an average of 64.51 out of 100 (SD = 29.42), and the probability of living to 85 
yielded a mean of 43.14 out of 100 (SD = 33.45). After diagnosis, the self-rated probability of 
living to 75 had a mean of 56.98 out of 100 (SD = 30.97), and the probability of living to 85 
averaged 36.91 out of 100 (SD = 32.76). Because the mean age in the sample was over 75, self-
rated probability of living to 85 or more was utilized in subsequent analyses, as it was a more 
relevant measure for most participants based on their age. 
Other health behaviors. Data about other health behaviors relevant to cognition were 
also collected for analysis. These included frequency of vigorous exercise, on 5-point scales of 
3+ times per week, 1-2 times per week, 1-2 times per month, less than 1 time per month or never. 
Prior to diagnosis, 32.1% of the sample reported engaging in vigorous exercise nearly every day, 
and 65.2% reported that they “never” engage in vigorous exercise. Following diagnosis, 24.8% 
reported nearly daily vigorous exercise, while 71.5% reported that they never engage in vigorous 
exercise. 
 Drinking and smoking behaviors were also reported. Prior to diagnosis, 15.9% of the 
sample reported that they were currently smoking, while 83.6% said they were not. After 
diagnosis, 10.2% of the sample reported smoking currently, while 89.8% denied current 
smoking. The average number of days per week alcohol was consumed in the sample prior to 
diagnosis was 1.28 (SD = 2.26), with an average 0.78 (SD = 1.63) drinks consumed on reported 
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drinking days. The average number of days per week participants reported drinking alcohol after 
diagnosis was 1.08 (SD = 2.15), with the average number of drinks consumed on those days 0.57 
(SD = 1.27). 
Mortality. The HRS utilized information from the National Death Index to indicate 
whether a participant had died at a given point. For the purpose of the current study, a dummy-
coded variable was constructed to indicate mortality beyond the last measured time point (four 
years after diagnosis). That is, whether a participant had died by the next data collection time, 
between 4 and 6 years after cancer diagnosed (since the participant was still alive 4 years after 
diagnosis, and the next interview took place 2 years later). Information about cause of death was 
not available for this sample. For purposes of the analyses, the primary sample consisted of those 
who were still alive 4 years after diagnosis. 
Please see Table 2 for descriptive statistics of study variables prior to cancer diagnosis, 
and Table 3 for descriptive statistics of study variables (including treatment variables) at the time 
after cancer diagnosis. 
Data Analytic Plan 
 Descriptive statistics for demographic variables as well as for study variables were 
collected prior to diagnosis, as well as immediately following diagnosis. Correlation coefficients 
were calculated for all variables of interest at both pre- and post-diagnosis time points, as well. 
 Following the collection of descriptive statistics, a Latent Class Growth Analysis 
(LCGA) approach was utilized to identify the best fitting model of cognitive functioning 
trajectories over the course of six years (from pre-diagnosis to four years after diagnosis). A 
floating baseline methodology was used in order to anchor each participant’s trajectory to his or 
her year of cancer diagnosis, so that time 1 (T1) was measured two years prior to cancer 
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diagnosis, time 2 (T2) indicated cancer was diagnosed since the previous interview, and time 
points 3 (T3) and 4 (T4) were two and four years after the post-diagnosis time point, 
respectively. Thus, the trajectories of cognitive functioning in response to cancer diagnosis could 
be compared across participants, though they may have occurred in different calendar years.  
The Mplus statistical program then seeks to fit the best model of trajectories of cognitive 
functioning to the data, comparing increasing numbers of classes (trajectories) over the course of 
several analyses, until the best-fitting unconditional model was identified. The best-fitting 
unconditional model for the data was based on a number of numerical decision points (fit 
statistics such as entropy and the Akaike Information Criteria), and the number of classes that 
were theoretically most parsimonious (Lubke & Muthen, 2005).  
 Once the best-fitting unconditional model (number of latent classes of cognitive 
functioning) was found, several conditional models were analyzed, where covariates of 
membership in the classes of cognitive functioning were analyzed. These separate conditional 
models assessed which demographic, psychological, and health variables predicted a 
participant’s membership in a particular trajectory of cognitive functioning.  
 Of particular relevance to the main hypothesis of this study was a conditional model 
investigating whether chemotherapy predicted membership in any of the classes of cognitive 
functioning (when compared to treatment with surgery and radiation). Additionally, logistic 
regression analyses were run to assess the impact of demographic variables on type of treatment 
received. Conditional models analyzing depression both before and at diagnosis, self-reported 
health and self-rated probability of living to the age of 85 prior to diagnosis, and ADLs at 
diagnosis, were also investigated. Possible demographic predictors of cognitive class 
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membership, such as age, gender, level of education, and financial status after diagnosis were 
assessed.  
 Finally, because this is a sample of older adults, and cognitive status (particularly on a 
variable like total recall) is expected to decline somewhat with age (Li, Lindenberger, & 
Sikström, 2001), a known class analysis was run which stratified the sample into two age groups; 
under the age of 80 and age 81 and over, in order to assess possible trajectory and covariate 
predictor differences among these age groups. 
Results 
Hypothesized risk and protective factors (prior to diagnosis) 
 Correlations among potential risk and protective factors related to total recall, as well as 
demographic and outcome variables collected in the wave prior to cancer diagnosis, are reported 
in Table 4. Race and education were significantly related to total recall, with individuals of 
minority status and those with fewer years of education manifesting lower recall. Additionally, 
poorer self-reported health and more difficulty with ADLs were significantly associated with 
lower recall. A higher self-rated probability of living to the age of 85 was significantly correlated 
with better recall, as was better self-rated memory status. Depressive symptoms were also 
significantly associated with total recall prior to cancer diagnosis, with more symptoms related to 
lower recall.  
Hypothesized risk and protective factors (after diagnosis) 
 Correlations among hypothesized risk factors, demographic and outcome variables in the 
wave immediately following diagnosis are reported in Table 5. Similar to the pre-diagnosis 
wave, race and education were significantly associated with total recall, with minority status and 
fewer years of education associated with lower cognitive functioning. Additionally, gender and 
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age at diagnosis were significantly correlated with total recall in this wave, with male gender and 
older age at diagnosis associated with lower cognitive functioning. Self-reported health, self-
reported memory and finances were also significantly related to total recall, with poorer health, 
memory and fewer financial assets associated with lower cognitive functioning.  More symptoms 
of depression were also significantly associated with lower cognitive functioning in this wave.  
 Of the outcome variables added to the correlation matrix after diagnosis, treatment with 
chemotherapy was significantly associated with higher cognitive functioning. Neither treatment 
with surgery or with radiation was associated with total recall. Difficulty with activities of daily 
living post-diagnosis was also significantly correlated with lower cognitive functioning. Those 
measures significantly related to total recall were subsequently analyzed in the latent growth 
curve analysis (LCGA) conditional models. 
Comparison of study variables before and after diagnosis  
 A series of paired-sample t-tests were run in order to investigate whether study variables 
of interest differed between the time prior to diagnosis and the data collection point after 
diagnosis. Depressive symptoms were significantly worse after diagnosis than prior to diagnosis 
in this sample (t = -4.82, p<.001). Self-reported health was also significantly worse after 
diagnosis than before diagnosis (t = -11.24, p<.001). When investigating differences in difficulty 
with ADLs from pre- to post-diagnosis, a significant increase in reported difficulty was found (t 
= -2.79, p<.001). There was no significant difference in self-rated probability of living to the age 
of 85 from pre- to post-diagnosis (t = -1.20, p=.23). 
 Regarding the difference in total recall scores over time (between four years prior to 
diagnosis and four years after diagnosis at two-year data collection intervals), a series of paired-
sample t-tests was performed. Total recall at two years prior to the pre-diagnosis time was not 
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significantly different from total recall at the pre-diagnosis time point (t = 1.911, p>.05). 
However, total recall after diagnosis was significantly lower than total recall prior to diagnosis (t 
= 2.57, p<.05). When the difference in total recall was investigated from post-diagnosis to two 
years later, there was a significant difference (t = 2.14, p<.05), with total recall at the later time 
point lower than at the post-diagnosis time. Total recall continued to be significantly lower four 
years after diagnosis when compared to two years after diagnosis (t = 2.91, p<.01). In the sample 
overall, total recall decreased significantly in every time window after the initial diagnosis. 
Unconditional model 
A latent class growth analysis (LCGA) approach was performed using Mplus version 7.0 
(Muthen & Muthen, 1998-2010), in order to identify the optimal number of trajectories of 
cognitive functioning for the sample, using total recall as the dependent variable to be modeled. 
A series of models with an increasing number of possible classes (or, latent populations of 
cognitive functioning) were compared - categorizing participants into one, two, and three classes. 
For purposes of model identification and convergence, the intercept, slope and quadratic terms 
were fixed for all analyses (Jung & Wickrama, 2008). 
In order to identify the number of classes that best fit the data, several fit criteria were 
assessed. These fit criteria were the Akaike information criteria (AIC), the regular and sample-
size-adjusted Bayesian information criterions (BIC and ssBIC), entropy values, Lo-Mendell-
Rubin test (LMR), and bootstrap likelihood-ratio tests (BLRT). Values of these fit criteria are 
presented in Table 6, presented in order of number of classes. In order to identify the best-fitting 
model, values of the above-mentioned fit statistics were taken into account, along with 
theoretical considerations and parsimony of interpretation (Lubke & Muthen, 2005). 
Investigation of the models began at one class, and increased in class number until the optimal 
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number of classes was identified. As the models increased from one to two classes, and again 
from two to three classes, improvements were seen in all fit criteria. However, a four class model 
failed to show a decrease in the AIC and BIC (which is the hallmark of improved model fit), and 
a non-significant bootstrap likelihood-ratio test. Additionally, the four-class model split the 
classes so that the fourth and smallest class was made of less than 2% of the sample, which is 
neither a parsimonious solution nor does it add any theoretical clarity. Thus, a three-class model 
of total recall over time was found to be the best-fitting model (see Figure 1). 
The largest of the three classes was the Middle Recall Class (52% of the sample), with an 
average stable total recall score across all time points. This class was characterized by a median 
initial intercept (b = 9.54, S.E. = 0.29, p<.001), a non-significant negative slope (b = -0.52, S.E. = 
0.31, p=.09), and a non-significant quadratic parameter (b = -0.01, S.E. = 0.09, p=.92). The 
second, and second largest of the three classes was the Lower Recall Class (30% of the sample), 
with a lower intercept and lower recall over time. This class was characterized by a low initial 
intercept (b = 5.52, S.E. = 0.37, p<.001), a non-significant negative slope (b = -0.43, S.E. = 0.42, 
p=.31), and a non-significant quadratic parameter (b = 0.01, S.E. = 0.13, p=.97). The third, and 
smallest class, was the High Recall Class, characterized by a high initial intercept (b = 12.90, 
S.E. = 0.59, p<.001) and continued high recall across time points. This class was also 
characterized by a non-significant (though slightly positive) slope (b = 0.02, S.E. = 0.54, p=.97), 
and a non-significant quadratic parameter (b = -0.12, S.E. = 0.16, p=.47). These three classes of 
cognitive functioning are presented in Figure 1. 
Conditional model with treatment type as a covariate 
In order to assess the impact of receiving chemotherapy treatment on cognitive 
functioning, compared to receiving surgery or radiation treatment, the three-class solution was 
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run as a conditional model using treatment type as a covariate. In order to proceed with 
interpretation of this conditional analysis, fit statistics such as Akaike Information Criteria (AIC), 
Bayesian Information Criteria (BIC), and entropy values were investigated for similarity to the 
unconditional model, as well as the retention of the original three classes. Since these fit criteria 
values and three class proportions were comparable to the unconditional model, the conditional 
model results for treatment type as covariate were analyzed, with results reported in Table 7. 
For the first set of analyses, the High Recall Class was used as the comparison group. 
Compared to the High Recall Class, individuals in both the Middle Recall and Low Recall 
Classes were significantly less likely to have received treatment with chemotherapy. Treatment 
with surgery and treatment with radiation did not predict membership in either the Middle or the 
Low Recall Class when compared to the High Recall class. 
Next, the Low Recall class was used as the comparison group to investigate probability 
of class membership by treatment type. When compared to the Low Recall Class, participants in 
the High Recall Class were significantly more likely to have received treatment with 
chemotherapy. There was no difference in likelihood of class membership for treatment with 
surgery or radiation. None of the treatment type differentiated membership between the Low 
Recall and Middle Recall Classes. 
Logistic regression using demographics to predict treatment type 
 In order to better understand the finding that treatment with chemotherapy predicted 
membership in the High Recall class, logistic regression analyses were performed to determine 
whether demographic characteristics predicted receipt of a particular treatment type. The 
demographics added into the model as possible predictors of treatment type were finances at 
onset of illness, education, race, and age at onset. 
30 
	  
 When predicting treatment with radiation, the model including all demographic variables 
only explained 6% of the variance above the intercept model. The only significant predictor of 
receiving radiation was age at onset (β = .939, p<.01), with younger individuals more likely to 
receive radiation than older individuals (see Table 8). Finances, education, and race, did not 
predict receipt of radiation therapy. 
 The next logistic regression was run to assess demographic predictors of treatment with 
surgery (see Table 9). The full model only predicted 4% of the variance in treatment with 
surgery above the intercept model, and none of the demographic variables investigated 
significantly predicted treatment with surgery. 
 Finally, a logistic regression was used to analyze predictors of treatment with 
chemotherapy (see Table 10). In contrast to the other two models, demographic factors predicted 
more variance in receipt of chemotherapy (11%), with younger age significantly increasing the 
likelihood of receiving chemotherapy (β = .921, p<.001). 
Conditional model with depression as a covariate  
In order to assess the impact of depressive symptoms (both pre-diagnosis and following 
diagnosis) on cognitive functioning, the three-class solution was run as a conditional model using 
depression as a covariate. Similar to the conditional model described above, fit statistics and 
class proportions were determined to be in line with the unconditional model before proceeding 
with interpretation of this conditional model. Since these criteria were met, the conditional model 
results for depression as covariate were analyzed, with results reported in Table 11. 
When compared to the Low Recall Class, pre-diagnosis depression did not significantly 
predict membership in either the Middle Recall or High Recall classes. However, fewer 
depressive symptoms post diagnosis did significantly predict membership in both the Middle 
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Recall and High Recall Classes, when compared to the Low Recall Class. When compared to the 
Middle Recall Class, pre-diagnosis depression was also not predictive of membership in either 
the Low or High Recall Classes. Those in the Low Recall Class had significantly more 
depressive symptoms post-diagnosis than those in the Middle Recall Class. 
Conditional model with health factors as covariates  
A conditional model was investigated, with self-reported health pre-diagnosis, reported 
probability of living to the age of 85 pre-diagnosis, and ADLs after diagnosis, entered as 
covariate predictors of class membership. Results from these analyses are reported in Table 12, 
since this model demonstrated adequate fit and retention of class proportions from the 
unconditional model. 
When compared to the High Recall Class, individuals in the Middle Recall Class reported 
a significantly lower probability of living to the age of 85 pre-diagnosis. There were no 
differences between the Middle Recall and High Recall classes on self-reported heath pre-
diagnosis, or difficulty with ADLs after diagnosis. Individuals in the Low Recall Class reported a 
significantly lower probability of living to the age of 85 pre-diagnosis as well, and reported 
significantly more difficulty with ADLs post-diagnosis than did those in the High Recall Class. 
When compared to the Middle Recall Class, individuals in the High Recall Class reported 
a significantly higher probability of living to the age of 85 (assessed pre-diagnosis). Neither self-
reported health pre-diagnosis, nor difficulty with ADLs post-diagnosis, differentiated the Middle 
and High Recall Classes. When the Low Recall Class was compared to the Middle Recall Class, 





Conditional model with demographic factors as covariates  
In order to investigate demographic predictors of class membership, a conditional model 
was run using age, gender, education level, financial assets, and marital status as covariates (see 
Table 13). To aid in model convergence, age and financial assets were standardized before they 
were entered into the regression model. Of note, age at diagnosis, non-housing financial assets at 
diagnosis, and marital status at diagnosis were utilized in this model. 
In the first analysis, the High Recall Class was used as the comparison class. Compared 
to the High Recall Class, both the Middle and Low Recall Classes were significantly older, more 
likely to be male, and to have a lower level of education. There were no differences in class 
membership based on financial assets between the Middle and Low Recall Classes and the High 
Recall comparison class. The Low Recall Class was significantly less likely to be married at the 
time of diagnosis than the Higher Recall Class. There was no difference in marital status between 
the Middle and High Recall Classes. 
Subsequently, when compared to the Low Recall Class, individuals in the High Recall 
Class were significantly more likely to be younger, female, have a higher level of education, and 
have been married at the time of diagnosis. Those in the Middle Recall Class were significantly 
older, and have a higher level of education than those in the Low Class. There was no difference 
between classes based on financial assets in this model. Additionally, the Low and Middle Recall 
Classes did not differ based on gender or marital status at diagnosis. 
Conditional model with known class (stratified by age) 
 To examine the effects of age on the trajectories of cognition, the chosen three-class 
solution from the unconditional model was analyzed using age as a known class variable. In 
order to do this, the sample was split into two groups- those under the age of 80 at diagnosis 
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(62.5% of the sample) and those over the age of 80 at diagnosis (37.5% of the sample). The 
results of this analyses indicated the same three classes among participants under the age of 80 as 
those over the age of 80, with entropy of .847 indicating the model continued to adequately fit 
the data when the known class variable was included (see Figure 2). 
 In the under 80 group, 17.5% were classified into the High Recall Class, 57.5% into the 
Middle Recall Class, and 25% were classified into the Low Recall Class. In the over 80 group, 
13.2% were classified into the High Recall Class, 49.3% were classified in to the Middle Recall 
Class, and 37.5% were classified into the Low Recall Class. 
 Multinomial regression analyses were conducted, testing difference in likelihood of class 
membership based on the known class variable, using the High Recall Class as the reference 
class. Results indicated no difference in membership likelihood for the Low Recall Class (b=-
0.55, S.E.=0.39) when compared with the High Recall Class. However, being over the age of 80 
made it significantly more likely to belong to the Middle Recall Class than the High Recall Class 
(b=2.22, S.E.=0.48, p<.01). Finally, parameter estimates (intercept, slope and quadratic) did not 
differ significantly between the two age groups for any of the cognitive classes. 
Conditional model of treatment type by age interaction 
 In order to further investigate the finding that individuals treated with chemotherapy were 
more likely to belong to the High Recall Class, another conditional model for treatment type was 
run, this time entering age group x treatment type as an interaction term. In this model, the High 
Recall Class was again used as the reference class. When the interaction terms were included in 
this analysis, the only significant interactions were between treatment with chemotherapy and 
age group. That is, when compared with the High Recall Class, individuals in the Middle Recall 
Class who were treated with chemotherapy were significantly more likely to be under the age of 
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80 (b=-1.92, S.E.=0.96, p<.05). There were no interactions between age group and either 
treatment with surgery or radiation on total recall class. 
 Of note, when age group was entered into this model in addition to treatment type and the 
age x treatment type interaction terms, chemotherapy was no longer a significant predictor of 
membership in the High Recall Class. That is, the interaction between age and treatment with 
chemotherapy appears to have been driving the previous finding of increased membership 
likelihood in the High Recall Class after treatment with chemotherapy. 
Discussion 
 Results of the present study indicate that, among older adults with cancer, demographic, 
treatment, psychological and other health factors are associated with cognitive functioning over 
time. When the cognitive functioning of this sample was investigated over the course of six 
years, three fairly stable trajectories of total recall were identified (High Recall, Middle Recall 
and Low Recall, with Middle Recall as the modal trajectory). In contrast to a significant body of 
research on cognitive impairment associated with chemotherapy (e.g. Ahles et al., 2002; Vardy 
& Tannock, 2007), this study did not evidence an association between treatment with 
chemotherapy and lower cognitive functioning over time. In fact, treatment with chemotherapy 
initially appeared to be related to higher functioning cognition trajectories, though after further 
analysis, this relationship is moderated by age of the individual undergoing treatment. In contrast 
to the treatment factors investigated, depressive symptoms post-diagnosis, demographic factors 
such as age and education, activities of daily living and self-rated probably of living to the age of 
85 did significantly predict membership in certain cognitive classes.  
In light of these findings, it is important to understand which factors put older adults 
diagnosed with cancer at risk for negative cognitive outcomes, as well as which factors are 
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protective. Additionally, the results of this study have important implications for early 
intervention and health care policy as it relates to older adults, as well as provide information 
about possible outcomes based on a variety of factors at pre- and post-diagnosis. This line of 
inquiry is especially important as the population ages in greater proportion, and rates of cancer 
incidence and cancer survival increase. Understanding the long-term impact of cancer and its 
treatment on cognitive functioning as it relates to many other psychological, health and quality of 
life factors, will hopefully aid in the ability of older adult cancer survivors to live out their lives 
with health and greater meaning – an outcome that greatly benefits society as a whole. 
Identifying risk and protective factors 
 Treatment factors.  From the results of this study, it appears that undergoing a particular 
cancer treatment (radiation, chemotherapy or surgery) does not impede cognitive functioning 
over the long run (specifically, none of the treatments listed predicted membership in the Low 
Recall Class). In fact, a surprising finding in this study was that treatment with chemotherapy 
predicted membership in the High Recall Class. In order to better understand the mechanisms 
behind this association, further analyses were undertaken. Since it seemed possible that there 
could be other variables, such as socioeconomic status and race, that could be highly correlated 
with treatment type received and have implications for cognitive functioning, logistic regression 
analyses using demographic variables to predict treatment type were run. In these analyses, only 
age emerged as a predictor of treatment type (with younger age predicting treatment with both 
chemotherapy and radiation, but not surgery). Since younger age was a significant predictor of 
treatment, the conditional model of treatment type was re-analyzed, with age (stratified into 
under and over the age of 80) and age by treatment type interactions added as possible predictors 
of cognitive class. 
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 When these additional covariates were added, several clarifying findings emerged. First, 
treatment with chemotherapy was no longer associated with membership in the High Recall 
Class. However, there was a significant age by treatment type interaction, showing that 
individuals in the High and Middle Recall Classes who had received treatment with 
chemotherapy were significantly more likely to be under the age of 80. That is, younger 
individuals were more likely to have received this treatment than older individuals to begin with 
(as seen in the logistic regression findings), and they were more likely to have been in the High 
and Middle Recall Classes. Thus, it appears that the original finding that chemotherapy improves 
likelihood of better cognitive functioning over time is at least somewhat confounded by age – 
indicating that younger age is a protective factor against cognitive decline in the long term, 
regardless of whether chemotherapy treatment is used. 
 This finding is interesting for several reasons. While it is intuitive and well documented 
that some cognitive decline is natural with age (Li, Lindenberger, & Sikström, 2001), it does not 
explain the age by chemotherapy interaction. Indeed, the vast majority of research on CICI has 
been conducted in middle-aged adults younger than the “young” sample studied here (aged 62-
80), with findings still showing cognitive difficulties (Vardy & Tannock, 2007). However, there 
have also been many studies failing to show a link between chemotherapy treatment and 
cognitive decline (e.g. Donovan et al., 2005; Jenkins et al., 2006; Keating, Nørredam, Landrum, 
Huskamp, & Meara, 2005; Porter, 2013; Shaffer et al., 2012).  
It is certainly possible that younger individuals are more likely to receive chemotherapy 
in general based on ageist perceptions that older individuals are less likely to survive their 
cancer, or tolerate the course of treatment without serious detriment to their health (Bond et al., 
2003; Janssen-Heijnen et al., 2007; Peake, Thompson, Lowe & Pearson, 2003). Another possible 
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explanation is that those younger individuals in the sample have been diagnosed early, and are 
thus likely to have better outcomes on a variety of cognitive and health variables post-treatment 
regardless, especially as treatments advance and rates of survival improve (Siegel et al., 2012). 
Additionally, there may be a difference in treatment type by cancer type for these individuals not 
able to be captured in the present study due to limited data on these factors, although a previous 
study utilizing the HRS dataset failed to find an association among cancer type, treatment type, 
and depression (Burton, Bonanno, & Galatzer-Levy, 2014). Whatever the reasons, the results of 
the present study indicate that for “younger” older adults, treatment with chemotherapy as well 
as their age bode well for positive cognitive sequelae over time.  
 Importantly, when age was added as a covariate, chemotherapy (and neither of the other 
cancer treatments investigated) did not predict membership in any of the cognitive classes 
identified in this study. Though the interview time points were widely spaced, making a more 
nuanced investigation of real-time cognitive side effects during treatment logistically difficult 
(and could certainly explain the difference among this study’s findings and those studies 
exploring cognitive decline during and immediately following chemotherapy treatment), it is 
hopeful that in the long term, among cancer survivors, chemotherapy did not be found to 
increase the likelihood of negative cognitive outcomes, even if some cognitive side effects of 
treatment were initially experienced and not captured in this dataset. Indeed, Schagen et al. 
(2002) noted no enduring cognitive symptoms after several years in a sample that had previously 
shown significant problems associated with their treatment. Though it is impossible to say 
whether such symptoms may have been experienced in this sample, the long-term lack of 
association between chemotherapy and negative cognitive outcomes, even in an older sample 
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potentially more susceptible to such changes (Puts et al., 2012), is both noteworthy and 
heartening. 
 Demographic factors. Many studies have shown that demographic factors are associated 
with health and cognitive outcomes across the lifespan, and among older adults in particular (e.g. 
Proust-Lima et al., 2008; Rabbitt, Donlan, Watson, McInnes, & Bent, 1995). Theoretical 
concepts like cognitive reserve postulate that protective factors like intelligence and level of 
education help bolster older individuals against experiencing cognitive decline, even along with 
neurodegenerative processes (Stern, 2003). 
 In line with these findings, results of this study showed that compared with the Low 
Recall Class, individuals in the High Recall Class were more likely to be younger, female, have 
more years of education, and be married. Compared to the Low Recall Class, those in the Middle 
Recall Class were more likely to be younger, and have more years of education.  
 Education level as a buffer against cognitive decline has been well documented, both in 
the cognitive reserve literature (Stern, 2009), and in its potential association with intelligence and 
career choices, all of which have been shown to bolster cognitive functioning in late life 
(Whalley, Deary, Appleton, & Starr, 2004). Research has also shown bolstering of “neural 
reserve” in more educated individuals with the mediation of structural changes in the 
hippocampus, another potential explanation for this association (Piras, Cherubini, Caltagirone, & 
Spalletta, 2011). 
 Because of some expected minimal cognitive decline associated with age, as well as the 
possibility that the older individuals in this sample may have also begun to be affected by 
neurodegenerative processes in addition to the sequelae of cancer (Bäckman, Jones, Berger, 
Laukka, & Small, 2005), the association between younger age and the Middle and High Recall 
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Classes makes sense. In contrast to the findings in the present study, women have been shown to 
have greater decline in cognitive outcomes in late life than men, possibly related to a longer life 
expectancy and thus more health problems that might affect cognition among older women 
(Karlamangla et al., 2009). 
 Also of interest was the likelihood of being in the High Recall Class if married at 
diagnosis, and the accompanying likelihood of being in the Low Recall Class if single at 
diagnosis. There are several possible ways to understand this finding. Firstly, having a partner 
during an illness has been shown to increase positive outcomes (Pienta, Hayward, & Jenkins, 
2000), which could very well include and affect cognitive functioning for a variety of reasons 
ranging from emotional support to help with proper medication adherence. Additionally, 
individuals who are married in later life have many other positive psychosocial and health 
benefits, including lower depression (Schoevers et al., 2000) and more social and intellectual 
stimulation (Fratiglioni, Paillard-Borg, & Winblad, 2004), all possible protective factors against 
lower cognitive functioning among older adults. 
 Finally, it is noteworthy that no association was found between financial status at the 
onset of cancer and cognitive functioning trajectory. In much of the literature on health outcomes 
in late life, individuals of lower socioeconomic status have been shown to be at particular risk for 
a host of negative health and psychosocial outcomes due to lack of resources and access to 
quality healthcare (Seeman et al., 2004). It’s possible that, in the present investigation, other 
factors like education and general health accounted for a greater proportion of the variance in 
cognitive status, or that possible associations between cognitive and socioeconomic status would 
have preceded the first data collection point. That is, an individual whose finances and access to 
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resources affected their cognitive functioning over time may have been affected across the 
lifespan in ways not captured by the variables in this study.  
 Depressive symptoms and cognition. The literature on depression and cognition in late 
life has found that depressive symptoms are generally associated with cognitive deficit (Butters 
et al., 2000). In particular, cognitive deficits that mimic cognitive symptoms associated both with 
cancer and with cancer treatment (Silberfarb, Philibert, & Levine, 1980). Hence, it was of 
interest to explore whether depressive symptoms would predict a degree of total recall by 
predicting membership in a particular class of cognitive functioning. To address questions of the 
relationship between depressive symptoms and cognitive functioning, depressive symptoms prior 
to a cancer diagnosis were explored as a predictor of membership in a particular cognitive 
functioning class. Unlike other studies, which have provided evidence of the relationship 
between depression and cognitive dysfunction in later life (McClintock, Husain, Greer, & 
Cullum, 2010), pre-diagnosis depressive symptoms did not predict membership in any of the 
three cognition classes in this study. However, the fact that subclinical depression was found in 
this sample may account for the difference. That is, it is possible that a clinical population with 
greater depressive symptom severity may have showed a greater association between depressive 
symptoms prior to diagnosis and cognitive outcome. 
 In contrast, post-diagnosis depressive symptoms did differentially predict membership in 
the cognitive trajectories identified in this study. Specifically, individuals in the Low Recall class 
were more likely to have a higher rate of depressive symptoms following a cancer diagnosis than 
did individuals in either the Middle or High Recall classes. Interestingly, pre-diagnosis 
depressive symptoms did not differentiate among the recall classes. It is also possible that for this 
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sample, having middle or higher levels of cognitive functioning may be protective against 
depressive symptoms following a cancer diagnosis.  
This finding has important implications for intervention, and identifying individuals 
potentially at risk for worse cognitive outcomes following cancer treatment, and prioritizing 
access to treatment for those individuals. Because it has been shown that treatment of depression 
in late life also improves cognitive performance (Butters et al., 2000), being able to identify 
individuals who show symptoms of depression immediately following diagnosis, and beginning 
treatment immediately, may protect against cognitive decline, and offer other health benefits as 
well. Additionally, the knowledge that post-diagnosis best predicts lower cognitive functioning 
will allow health care professionals to target the most optimal time for intervention.  
 Physical health and functioning factors. In addition to the psychological, demographic 
and treatment variables described above, other physical health and functioning factors were 
found to affect membership in particular cognitive classes. Specifically, more difficulty with 
activities of daily living post-diagnosis and lower self-rated probability of living to age 85 pre-
diagnosis predicted membership in the Low Recall Class, compared to the High Recall Class. 
Self-rated health was not predictive of class membership in this study. 
 Activities of daily living have been associated with a variety of health and cognitive 
outcomes among older adults (McGuire, Ford, & Ajani, 2006), as well as a reliable barometer for 
general health status (Freedman et al., 2013). Indeed, in a study examining various predictors of 
worsening cognitive trajectories among older adults, ADLs more accurately tracked a worsening 
trajectory than number/length of hospitalizations (Han, Gil, Jones, & Allore, 2015). Though 
these associations have been well documented and were replicated in this study, the fact of lower 
functioning immediately after diagnosis affecting cognitive functioning years later indicates this 
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is a critical period for intervention and bolstering of ADLs among newly diagnosed older adults. 
It is possible that encouraging physical exercise in moderation and recommending caregivers to 
allow ill individuals to perform ADLs on their own, a potentially difficult task for someone 
coping with cancer and those taking care of them, could help avoid some negative cognitive 
outcomes (e.g. Wolinsky et al., 2011). It is possible that psychoeducation for family members 
and caregivers could help increase understanding and implementation of beneficial regimens to 
improve functioning, or at least ensure ADLs remain stable.  
 The self-rated probability of living to the age of 85, when measured two years prior to 
diagnosis, was also predictive of membership in the High Recall Class. Though potentially 
related to other psychological and sociodemographic factors, this measure of perceiving 
longevity and optimism about longevity appears to confer protective benefits. The degree to 
which such optimism may protect against cognitive decline even when dealing with a major 
illness has been found among heart attack survivors, who are more likely to survive for years 
after the health crisis (Galatzer-Levy & Bonanno, 2014). In line with this finding, a study 
conducted by Levy, Ashman, and Dror (2000) found that older adults who did not have hope for 
longevity were more likely to have negative health outcomes that affected their mortality (though 
it is possible this finding could work both ways). Longitudinal research has also been done in 
this area, highlighting the detrimental physical health consequences of negative health views, in 
addition to psychological consequences such as feeling a lack of control over one’s health and 
future (Wurm, Tesch-Römer, & Tomasik, 2007). These examples, coupled with the findings in 
this study, show the potential for optimism to be related to important and concrete benefits for 




Recommendations for health care professionals and others 
 The findings from this study provide valuable information about risk and protective 
factors related to cognitive functioning among older adults with cancer, as well as optimal timing 
for effective interventions. Based on these results, there are several recommendations that can be 
made to health care providers who work with this population, as well as to family members and 
caregivers, to best support optimal functioning and sustaining a positive and meaningful quality 
of life in remission. 
 Since there were many factors, across domains, that were found to affect cognitive 
functioning over time, it will be important for health care professionals to keep in mind, first and 
foremost, that cognition in older adults with cancer is multifaceted, and cannot be addressed in a 
vacuum. Taking a more holistic approach to physical health that includes psychological, 
emotional, basic functioning and other health variables will help doctors and other health care 
providers best address concerns about cognitive functioning as it relates to other important 
factors in a person’s life, as well as their ultimate quality of life and sense of meaning. For 
example, inquiring about depressive symptoms, ADLs, and mindset/optimism during routine 
visits, in addition to frequent screening for cognitive status, will allow medical professionals to 
get a better sense of the interplay of psychosocial and health factors for each individual patient, 
so that they may recommend early and appropriate interventions based on targeted information. 
 Though there has been a concerted effort to address and reduce ageism among 
physicians, starting from medical school training (Hurria et al., 2008), there remain problematic 
assumptions made about the cognitive functioning and health status of older adults (Leung, 
LoGiudice, Schwarz, & Brand, 2011), especially when illness such as cancer is involved 
(Schroyen, Adam, Jerusalem, & Missotten, 2015). Educating health care providers about the 
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multiple contributors to lowered cognitive functioning among older adults in general and cancer 
patients in particular may help to refocus their efforts on intervention, greater vigilance about 
screening for cognitive complaints, and working with individuals and their families to address 
possible contributors to cognitive difficulties, such as depression (Keefe, 2016).  
Hopefully, armed with this knowledge, doctors will be less likely to exclude older adults 
from certain treatments and clinical trials based on the perception that they won’t be able to 
“handle them,” or based on concern about altered cognitive states (Townsley, Selby, & Siu, 
2005). This is especially problematic when the patient internalizes these negative beliefs, leading 
to increased risk for health problems and mortality (Levy, 2003). Finally, helping providers to 
adopt the perspective that stable to high cognitive functioning over time is the modal outcome, 
even after experiencing cancer and cancer treatment, will hopefully aid in enhancing positive 
perceptions of living well in late life, even after illness. 
 The results of this study in regard to the effects of chemotherapy on cognitive functioning 
were heartening, and diverge from much of the literature about CICI in cancer patients. Though 
there are some possible methodological reasons for this finding, there are other possibilities as 
well. Advances in oncology over the last 20 years have led to new approaches in regard to the 
types, doses and lengths of chemotherapy treatment, including targeted therapies based on 
genetic variants of certain cancers (Slamon, Romond, & Perez, 2006). These advances have also 
included medications that allow for greater patient tolerance of treatment regimens and fewer 
side effects (e.g. Cortes & Saura, 2010).  Other treatments for cancer such as laparoscopic 
surgery (Darzi & Mackay, 2002) and targeted radiation (Baskar, Lee, Yeo, & Yeoh, 2012), as 
well as improved screening and early detection of these diagnoses (Brenner, Gondos, & Arndt, 
2007), have also led to impressive changes, with improvement seen in the survival rates for 
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many cancers (Siegel et al., 2012). In light of these advances, health care professionals may not 
need to be quite as cautious about recommending certain treatments to older patients, especially 
in light of the lack of adverse consequences from chemotherapy in this study. However, it is 
important to note that, because of the age interaction and potentially biased survivorship sample, 
it is not possible to make generalizations about the reactions to chemotherapy treatment of all 
older adults newly diagnosed with cancer. Expecting that older individuals can live well for 
longer periods of time, and may not be as adversely affected by chemotherapy (particularly if 
they are under the age of 80 and have other protective factors against cognitive decline), may 
have the added benefit of widening the scope of treatments recommended, with ultimately 
improved outcomes. 
 Finally, implementation of psychoeducation for family members and caregivers around 
the various factors affecting cognition in older adults with cancer would be of tremendous 
benefit to both patients and their loved ones. Since these individuals spend the largest amount of 
time with the individuals affected, they can both be taught to be sensitive to important changes, 
and to seek intervention as needed. Also, knowledge that functioning well and maintaining a 
stable cognitive status over the long run is the modal response may be of emotional benefit to 
both patients and their families and caregivers. Such optimism may in turn provide health 
benefits, and may lead to higher rates of treatment, and to a greater quality of life.  
Limitations and Future Directions 
 Though the present study adds to an understanding of the factors affecting cognition 
among cancer patients in late life, it is important to acknowledge its limitations. Although the 
Health and Retirement Study allows for access to a large sample over a long period of time, 
including prospective information prior to a cancer diagnosis, the data lack specificity in certain 
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domains. First, there is limited information about type and severity of cancer, as well as about 
specific cancer treatments, dosing, and other important information about the cancer itself. 
Though a study using the same dataset did not find associations between cancer type and the 
depression trajectories associated with chemotherapy (Burton, Bonanno, & Galatzer-Levy, 
2014), these associations cannot be ruled out. Second, there was a long window between data 
collection periods (two years), so this study was unable to measure subtle cognitive changes in 
real time alongside treatments. Following, it is possible that individuals in this sample did 
experience declines in cognitive functioning related to certain treatments that were not able to be 
captured in the analyses performed here. It’s also possible that there was a selection bias in 
which individuals accepted recommendations for treatment with chemotherapy, which might 
have influenced the results. One study showed that while there was no difference between older 
and younger adults in acceptance of chemotherapy in a hypothetical medical scenario, there was 
a difference in the willingness to accept further toxic treatment in exchange for current quality of 
life at later disease stages (Yellen, Cella, & Leslie, 1994), further indicating the possibility that 
other factors are likely influencing treatment decisions among older adults. 
Third, there are inherent limitations in the use of self-report data (potential bias, 
omission, etc.) in relation to the health and treatment variables, as well as a lack of objective data 
confirming cancer and treatment status, and about difficulties with ADLs. Research on the 
cumulative effects of multiple health comorbidities have shown that greater allostatic load 
negatively affects cognition among older adults (McEwen, 2002), and therefore it is possible that 
other health problems experienced among the individuals in this sample might be affecting the 
findings. Future research would benefit from using both objective treatment data and records, as 
well as reports from caregivers or family members, in addition to patient self-reports. 
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 Because this study was conducted in a unique sample of older adults who had survived 
cancer, it will require further research to determine whether the relationships among cancer, 
cognition, psychological, health and demographic factors differ for individuals who passed away 
before the wave two years after diagnosis. Additionally, because these data were from a much 
larger study with a relatively small sample of individuals from minority groups, it is unclear 
whether these results would be found in a study in which there was oversampling for minority 
status. It would also be of interest to employ measures of cognitive functioning other than those 
measuring immediate and delayed recall (a measure of working and long-term memory), in order 
to determine differences in trajectories of functioning in a wider array of cognitive functions 
potentially affected by cancer, cancer treatment, and normal aging. It could also be that the way 
cognition was measured in this study is a relatively stable measure, that is, not sensitive enough 
to measure small changes that may affect functioning in daily life. 
Finally, this sample overall had fairly low levels of depressive symptoms, and relatively 
stable levels of cognitive functioning, likely due to the fact that the HRS data were not collected 
from a clinical sample. Certainly, the levels of depressive symptomatology in this sample of 
cancer survivors did not reach the levels reported in other studies, either in proportion or in 
severity, nor did the lack of a finding of CICI in any way mirror studies citing prevalence of this 
phenomenon up to 75% in some studies (Vardy & Tannock, 2007). It is possible that this sample 
of survivors were in better health, both physical and psychological, than those individuals in 
studies reporting lower functioning overall (Deimling, Kahana, Bowman, & Schaefer, 2002). 
 Future studies should sample in shorter intervals, use more sensitive and varied measures 
of cognitive functioning and other health factors in addition to objective health and treatment 
data (particularly taking into account health comorbidities such as diabetes and vascular risk 
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factors that might affect cognition, and qualitative information about decisions to undergo 
particular treatments), as well as attempt to assess differences between a sample who survived 
cancer and those who did not. Continuing to sample longitudinally to understand the 
relationships among these variables prospectively is advised, as it allows for the greatest control 
and specificity when understanding the onset, prevalence and outcomes of cognition and other 
psychosocial and health factors related to cancer among older adults. 
Conclusions 
Despite these limitations, the current study represents an important step toward 
understanding the various demographic, psychological, treatment and health factors that affect 
cognition among older adults with and surviving cancer. A longitudinal analysis was conducted 
in order to determine protective and risk factors associated with trajectories of cognitive 
functioning from before cancer diagnosis, immediately following diagnosis, and four years later. 
Risk factors for lower cognitive functioning included male gender, older age, fewer years of 
education, single marital status, post-diagnosis depressive symptoms, pre-diagnosis self-rated 
lower probability of living to the age of 85, and more difficulty with activities of daily living 
post-diagnosis. Treatment with chemotherapy did not predict membership in a lower functioning 
cognitive class, and in fact, when moderated by younger age, predicted membership in the higher 
functioning cognitive classes over time. Using this information, proposals are made for 
identifying individuals at greatest risk for negative cognitive sequelae at the time of diagnosis, as 






Table 1. Demographic characteristics (n=403) 
  Mean (SD) Range 
Age (At Diagnosis) 76.15 (8.0) 62-98 
Gender 
    Male 52.9% n=213 
  Female 47.1% n=190 
Race 
    Caucasian 86.6% n=349 
  African American 12.4% n=50 
  Other 1.0% n=4 
Years of Education 11.51 (3.64) 0-17 
Highest Level of Education 
 	    No Degree 33.3% n=134 
  GED 4.0% n=16 
  High School Diploma 29.8% n=120 
  High School Equivalent 15.1% n=61 
  Associates/Some College 2.7% n=11 
  Bachelors Degree 8.9% n=36 
  Masters/MBA 4.7% n=19 
  Law Degree/MD/PhD 1.5% n=6 
Relationship Status (At Diagnosis)   
   Married  57.1% n=230 
   Married, Spouse Absent  0.7% n=3 
   Partnered  2.2% n=9 
   Separated  0.2% n=1 
   Divorced  5.2% n=21 
   Separated/Divorced 2.2% n=9 
   Widowed 30.3% n=122 
   Never Married 1.7% n=7 
Financial Assets, Non-Housing (At Diagnosis)   
    <10,000  37.7% n=152 
    10,000-100,000  30.8% n=124 
     >100,000 28.3% n=114 
Religious Affiliation   
   Protestant 62.8% n=253 
   Catholic 27.8% n=112 
   Jewish 3.0% n=12 
   None/No Preference 4.5% n=18 





Table 2. Study variables pre-diagnosis (n=403) 
  Mean (SD) Range 
Total Recall (Immediate + Delayed Recall) 8.97 (3.64) 1-20 
Cognition Total Score (Mental Status + Memory) 21.50 (5.11) 5-32 
Vocabulary Score 5.50 (2.11) 0-10 
CES-D Depression Score 1.34 (1.80) 0-8 
Self-Reported Health 2.91 (1.11) 1-5 
  Excellent Health 11.9% n=48 
  Very Good Health 24.1% n=97 
  Good Health 32.0% n=129 
  Fair Health 25.6% n=103 
  Poor Health 6.5% n=26 
Difficulty with Activities of Daily Living 0.35 (0.85) 0-5 
Self-Reported Vigorous Exercise   
  Nearly Every Day 32.1% n=107 
  Never 65.2% n=217 
Currently Smoking   
  Yes 15.9% n=64 
  No 83.6% n=337 
Number of Days Per Week Drinking Alcohol 1.28 (2.26) 0-7 
Number of Alcoholic Drinks Per Day (When Drinks) 0.78 (1.63) 0-12 
Self-Rated Probability of Living Past 75 64.51 (29.42) 0-100 














Table 3. Study variables post-diagnosis (n=403) 
  Mean (SD) Range 
Total Recall (Immediate + Delayed Recall) 8.58 (3.42) 0-20 
Cognition Total Score (Mental Status + Memory) 20.95 (5.04) 6-35 
Vocabulary Score 5.34 (2.14) 0-10 
Received Chemotherapy 27.3% n=110 
Received Surgery 18.9% n=76 
Received Radiation 12.2% n=49 
CES-D Depression Score 1.83 (2.03) 0-8 
Self-Reported Health 3.52 (1.05) 1-5 
  Excellent Health 4.7% n=19 
  Very Good Health 10.7% n=43 
  Good Health 31.0% n=125 
  Fair Health 35.5% n=143 
  Poor Health 18.1% n=73 
Out of Pocket Medical Expenses 6329.01 (19004.50) 0-217500 
Difficulty with Activities of Daily Living 0.47 (0.99) 0-5 
Self-Reported Vigorous Exercise   
  Nearly Every Day 24.8% n=100 
  Nearly Never 71.5% n=288 
Currently Smoking   
  Yes 10.2% n=41 
  No 89.8% n=360 
Number of Days Per Week Drinking Alcohol 1.08 (2.15) 0-7 
Number of Alcoholic Drinks Per Day (When Drinks) 0.57 (1.27) 0-15 
Self-Rated Probability of Living Past 75 56.98 (30.97) 0-100 






Table 4. Correlation matrix for study variables pre-diagnosis  
 
 1 2 3 4 5 6 7 8 9 10 11 
1. GENDER            
2. RACE -.031           
3. EDUCATION -.035 -.277**          
4. SELF-REPORTED HEALTH .090 .098* -.312**         
5. DIFFICULTY WITH ADLS .035 .153** -.197** .336**        
6. FREQ VIGOROUS EXERCISE -.120* -.008 .124* -.228** -.172**       
7. PROB OF LIVING TO 75 -.136 .258* .304** -.444** -.213 -.051      
8. PROB OF LIVING TO 85 .000 .024 .079 -.255** -.025 .103 .724**     
9. TOTAL RECALL  .070 -.174** .367** -.149* -.184** .047 .185 .155*    
10. SELF-REPORTED MEMORY -.117* .063 -.197** .185** .274** .073 -.216 .044 -.164**   
11. COGNITION TOTAL SCORE .006 -.295** .500** -.164* -.250** .020 -.175 .037 .898** -.247**  
12. DEPRESSION .035 .087 -.228** .361** .393** -.174** -.214 -.217** -.204** -.051 -.243** 












Table 5. Correlation matrix for study variables post-diagnosis  
 
 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 
1. GENDER                 
2. RACE -.03                
3. EDUCATION -.03 -.28**               
4. AGE AT DIAGNOSIS .07 .04 -.10*              
5. FINANCES ONSET -.03 -.11* .26** .04             
6. CHEMOTHERAPY -.04 -.01 -.02 -.27** .02            
7. SURGERY .04 -.08 -.04 -.06 -.08 .03           
8. RADIATION -.03 -.02 .06 -.16** .08 .18** -.14*          
9. SELF-REP HEALTH .04 .10* -.17** -.05 -.05 .10 -.09 -.02         
10. DIFFICULTY ADL’S -.01 .06 -.10* .14** -.02 -.08 -.09 -.03 .23**        
11. VIG EXERCISE -.06 -.01 .11* -.09 .05 -.02 .01 -.01 -.19** -.14**       
12. PROB LIVING TO 75 -.04 .39** .03 -.10 .09 .13 .08 .08 -.37* -.24 .32*      
13. PROB LIVING TO 85 -.06 .04 .01 -.11 .09 -.02 -.04 -.03 -.32** -.04 .12 .81**     
14. TOTAL RECALL .14** -.17** .34** -.31** .13* .13* .07 .06 -.10 -.25** .08 .04 .01    
15. SELF-R MEMORY -.12** .08 -.12* .15** .01 -.05 -.01 .02 .10* .21** -.05 -.33* -.05 -.16**   
16. COGNITION TOT  .05 -.31** .48** -.22** .17** .12* .08 .08 -.18** -.28** .09 .21 .01 .89** -.19**  
17. DEPRESSION .08 .03 -.18** .03 -.11* -.06 -.01 -.09 -.36** .27** -.17** -.40** -.19** -.21** -.04 -.29** 





Table 6. Fit indices for one-four class unconditional growth curve analysis of total recall  
 
Model 
Fit index One class Two classes Three classes Four classes 
AIC 6454.49 6191.79 6091.23 6086.28 
BIC 6481.81 6234.72 6149.77 6160.43 
SSBIC 6459.60 6199.82 6102.18 6100.15 
Entropy - 0.68 0.74 0.79 
LMR - p<.01 p<.001 p>.05 
BLRT - p<.001 p <.001 p>.05 
Note: AIC = Akaike information criterion, BIC = Bayesian information criterion, SSBIC = sample-size-adjusted 
Bayesian information criterion, LMR = Lo-Mendell-Rubin test, BLRT = bootstrap likelihood-ratio test. Italics 
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Table 8. Logistic regression predicting treatment with radiation 
Predictor variable     B  SE B  β  
   
Constant      2.42  1.76  11.27 
Finances at Onset     .147  .119  1.16 
Years of Education     .027  .050  1.03 
Race       -.014  .457  .986 
Age at Onset      -.06  1.76  .939** 
 





















Table 9. Logistic regression predicting treatment with surgery 
Predictor variable     B  SE B  β  
   
Constant      -.102  1.50  .903 
Finances at Onset     -.649  .390  .523 
Years of Education     .036  .040  1.04 
Race       -.726  .448  .484 
Age at Onset      -.013  .016  .903 
 




















Table 10. Logistic regression predicting treatment with chemotherapy 
Predictor variable     B  SE B  β  
   
Constant      5.82  1.36  337.1 
Finances at Onset     .109  .112  1.12 
Years of Education     -.045  .035  .956 
Race       -.097  .332  .908 
Age at Onset      -.082  .016  .921*** 
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